Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Respiratory Syncytial Virus Infections 1Autoimmune Diseases 1

Interventions

Magnetic Resonance Spectroscopy 84Specimen Handling 83Cyclophosphamide 75pembrolizumab 64Radiotherapy 54Nivolumab 52fludarabine 44Cisplatin 40Biopsy 40Carboplatin 39Standard of Care 38Bevacizumab 32Dexamethasone 31Rituximab 29Gemcitabine 29venetoclax 27Surveys and Questionnaires 27Radiosurgery 27Radiation 27Temozolomide 26Practice Guidelines as Topic 26Paclitaxel 25Doxorubicin 25Blood Specimen Collection 25Cytarabine 24fludarabine phosphate 23Interviews as Topic 22atezolizumab 21Injections 20Capecitabine 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × remdesivir × 30 days × Clear all
NCT06817889 2026-06-03

Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals

Fred Hutchinson Cancer Center

Phase 2 Recruiting
60 enrolled

Autoimmune Diseases, Respiratory Syncytial Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡